 Home > Active Ingredient News > Antitumor Therapy > J Clin Oncol: Efficacy and safety of Durvalumab±Oleclumab/Monalizumab consolidation therapy in stage 3 non-small cell lung cancer

J Clin Oncol: Efficacy and safety of Durvalumab±Oleclumab/Monalizumab consolidation therapy in stage 3 non-small cell lung cancer

 Last Update: 2022-05-20
 Source: Internet
 Author: User

Tags

2a breast cancer

anti islet cell antibody

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Durvalumab is a selective, high-affinity human immunoglobulin G1 monoclonal antibody (mAb) that blocks programmed cell death ligand-1 (PD-L1) and programmed cell death-1 (PD-1) Binding to CD80 enables T cells to recognize and kill tumor cells

Durvalumab significantly improved overall survival in patients with unresectable stage III non-small cell lung cancer and was progression-free after concurrent chemoradiotherapy (cCRT)

Patients with composite inclusion criteria were randomized (1:1:1) to receive either Durvalumab monotherapy or Durvalumab+Oleclumab or Durvalumab+Monalizumab consolidation therapy within 42 days of cCRT for up to 12 months, stratified by histology

The objective response rates were 17.

In conclusion, compared with Durvalumab monotherapy, the two combination regimens can relatively improve the objective response rate and prolong the progression-free survival without increasing safety issues

Compared with Durvalumab monotherapy, both combination regimens can relatively improve objective response rate and prolong progression-free survival without increasing safety issues.

Original source:

Roy S.

Roy S.
Herbst, et al.
COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non–Small-Cell Lung Cancer.
J Clin Oncol.
https://ascopubs.
org/doi/full/10.
1200/JCO.
22.
00227

Leave a comment here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Gemcitabine Base 95058-81-4

CAS No.: 95058-81-4

$1-1.2/MT EXW

Amoxicillin Diketopiperazine

CAS No.: 2088961-37-7

Pharmacy Grade

$1.3-1.5/G FOB

Pentostatin powder High quality 99% Herbal extract White Powder cas 53910-25-1

CAS No.: 53910-25-1

Chemical Grade

$4-5/UNIT FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.